Pathology Diagnostics Ltd (PDL) Biomarker Test Portfolio and Advanced Staining Capabilities Show CAGR of 50%
Cambridge, United Kingdom, June 27, 2014 --(PR.com
)-- Due to the recent rapid growth of Pathology Diagnostics Ltd (PDL), the advanced laboratory staining biomarker test portfolio of the organisation has grown at an extremely impressive rate, with the number of biomarkers validated now reaching over 370 for immunohistochemistry (IHC) and immunofluorescence (IMF). This represents one of the largest test databases available at an industry histopathology CRO. The biomarkers range from traditional oncology biomarkers (cell signalling proteins, growth factors and metastatic markers) to other specialist biomarkers in niche disease therapy areas including neuronal and musculoskeletal diseases. We have validated novel biomarkers tests in current topical areas in oncology drug development, including the quantitative analysis of tissue biomarkers to monitor immunomodulatory therapies.
Pathology Diagnostics prides itself in continually extending its GCLP accredited central laboratory services for both early stage R&D studies and clinical trials, now with the addition of tests for central and peripheral nervous system and musculoskeletal disease monitoring. The ability to carry out such a varied range of studies is primarily due to the extensive background and expertise from the ever-growing team of experienced pharmaceutical industry and academic biomedical scientists.
Pathology Diagnostics Ltd now has an immunofluorescence lab and is developing the IMF test portfolio to include a wider range of double immunohistochemistry (IHC) and immunofluorescence (IMF) assays. Double IHC staining with DAB and AEC is becoming increasingly popular with clients, and has already been successfully validated on a variety of tissue types. Due to current customer requests, the organisation now has the capabilities to include triple IMF.
To cater for larger clinical trials Pathology Diagnostics is established to carry out high-throughput projects, within its Stirling House HTA licenced central biorepository and associated histopathology laboratories. We continue to offer the assurance of high quality GCP compliant histology and central pathology diagnostic services to our biotechnology and pharmaceutical industry clients.